CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Jeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, Laura F Newell, Tara L Lin, Ellen K Ritchie, Robert K Stuart, Stephen A Strickland, Donna Hogge, Scott R Solomon, Richard M Stone, Dale L Bixby, Jonathan E Kolitz, Gary J Schiller, Matthew J Wieduwilt, Daniel H Ryan, Antje Hoering, Kamalika Banerjee, Michael Chiarella, Arthur C Louie, Bruno C Medeiros, Jeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, Laura F Newell, Tara L Lin, Ellen K Ritchie, Robert K Stuart, Stephen A Strickland, Donna Hogge, Scott R Solomon, Richard M Stone, Dale L Bixby, Jonathan E Kolitz, Gary J Schiller, Matthew J Wieduwilt, Daniel H Ryan, Antje Hoering, Kamalika Banerjee, Michael Chiarella, Arthur C Louie, Bruno C Medeiros
Abstract
Purpose CPX-351 is a dual-drug liposomal encapsulation of cytarabine and daunorubicin that delivers a synergistic 5:1 drug ratio into leukemia cells to a greater extent than normal bone marrow cells. Prior clinical studies demonstrated a sustained drug ratio and exposure in vivo and prolonged survival versus standard-of-care cytarabine plus daunorubicin chemotherapy (7+3 regimen) in older patients with newly diagnosed secondary acute myeloid leukemia (sAML). Patients and Methods In this open-label, randomized, phase III trial, 309 patients age 60 to 75 years with newly diagnosed high-risk/sAML received one to two induction cycles of CPX-351 or 7+3 followed by consolidation therapy with a similar regimen. The primary end point was overall survival. Results CPX-351 significantly improved median overall survival versus 7+3 (9.56 v 5.95 months; hazard ratio, 0.69; 95% CI, 0.52 to 0.90; one-sided P = .003). Overall remission rate was also significantly higher with CPX-351 versus 7+3 (47.7% v 33.3%; two-sided P = .016). Improved outcomes were observed across age-groups and AML subtypes. The incidences of nonhematologic adverse events were comparable between arms, despite a longer treatment phase and prolonged time to neutrophil and platelet count recovery with CPX-351. Early mortality rates with CPX-351 and 7+3 were 5.9% and 10.6% (two-sided P = .149) through day 30 and 13.7% and 21.2% (two-sided P = .097) through day 60. Conclusion CPX-351 treatment is associated with significantly longer survival compared with conventional 7+3 in older adults with newly diagnosed sAML. The safety profile of CPX-351 was similar to that of conventional 7+3 therapy.
Trial registration: ClinicalTrials.gov NCT01696084.
Figures
References
- Vardiman JW, Thiele J, Arber DA, et al. : The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
- Granfeldt Østgård LS, Medeiros BC, Sengeløv H, et al. : Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study. J Clin Oncol 33:3641-3649, 2015
- Miesner M, Haferlach C, Bacher U, et al. : Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: A comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC). Blood 116:2742-2751, 2010
- Hulegårdh E, Nilsson C, Lazarevic V, et al. : Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry. Am J Hematol 90:208-214, 2015
- Leith CP, Kopecky KJ, Godwin J, et al. : Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323-3329, 1997
- Grimwade D, Hills RK, Moorman AV, et al. : Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354-365, 2010
- Rai KR, Holland JF, Glidewell OJ, et al. : Treatment of acute myelocytic leukemia: A study by cancer and leukemia group B. Blood 58:1203-1212, 1981
- Yates JW, Wallace HJ, Jr, Ellison RR, et al. : Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep 57:485-488, 1973
- Kayser S, Döhner K, Krauter J, et al. : The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 117:2137-2145, 2011
- Schoch C, Kern W, Schnittger S, et al. : Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): An analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 18:120-125, 2004
- Dombret H, Gardin C: An update of current treatments for adult acute myeloid leukemia. Blood 127:53-61, 2016
- Mayer RJ, Davis RB, Schiffer CA, et al. : Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896-903, 1994
- Burnett AK, Milligan D, Goldstone A, et al. : The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: The results of the LRF AML14 trial. Br J Haematol 145:318-332, 2009
- Stone RM, Mandrekar SJ, Sanford BL, et al. : Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454-464, 2017
- Hills RK, Castaigne S, Appelbaum FR, et al. : Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: A meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986-996, 2014
- Lim WS, Tardi PG, Dos Santos N, et al. : Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res 34:1214-1223, 2010
- Kim HP, Gerhard B, Harasym TO, et al. : Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol 39:741-750, 2011
- Mayer LD, Harasym TO, Tardi PG, et al. : Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5:1854-1863, 2006
- Tardi P, Johnstone S, Harasym N, et al. : In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 33:129-139, 2009
- Lancet JE, Cortes JE, Hogge DE, et al. : Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood 123:3239-3246, 2014
- Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
- Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 [Erratum: J Clin Oncol 22:576, 2004]
- Lichtman MA: A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells Mol Dis 50:119-130, 2013
- Feldman EJ, Kolitz JE, Trang JM, et al. : Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res 36:1283-1289, 2012
- Feldman EJ, Lancet JE, Kolitz JE, et al. : First-in-man study of CPX-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 29:979-985, 2011
- Leith CP, Kopecky KJ, Chen IM, et al. : Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: A Southwest Oncology Group Study. Blood 94:1086-1099, 1999
- Juliusson G, Antunovic P, Derolf A, et al. : Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 113:4179-4187, 2009
- Stone RM, Mazzola E, Neuberg D, et al. : Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol 33:1252-1257, 2015
- Willemze R, Suciu S, Meloni G, et al. : High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: Results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 32:219-228, 2014
- Holowiecki J, Grosicki S, Giebel S, et al. : Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: A multicenter, randomized phase III study. J Clin Oncol 30:2441-2448, 2012
- Araki D, Wood BL, Othus M, et al. : Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: Time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol 34:329-336, 2016
- Gordon MJ, Tardi P, Loriaux MM, et al. : CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res 53:39-49, 2017
- Walter MJ, Shen D, Ding L, et al. : Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 366:1090-1098, 2012
- Lindsley RC, Mar BG, Mazzola E, et al. : Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood 125:1367-1376, 2015
Source: PubMed